Abstract
Purpose
We investigated correlations of somatic BRAF V600E mutation and RET/PTC1 rearrangement with recurrent disease in Chinese patients with papillary thyroid carcinoma (ptc).
Methods
This prospective study included 214 patients with ptc histologically confirmed between November 2009 and May 2011 at a single institute.
Results
We found somatic BRAF V600E mutation in 68.7% and RET/PTC1 rearrangement in 25.7% of the patients. Although BRAF mutation was not significantly associated with clinicopathologic features such as patient sex or age, multicentric disease, thyroid capsule invasion, tumour stage, or nodal metastasis, it was significantly associated with recurrent disease. Multivariate analysis revealed that BRAF mutation and tumour size were independent risk factors associated with recurrent disease, with odds ratios of 9.072 and 2.387 respectively. The area under the receiver operating characteristic curve increased 8.3% when BRAF mutation was added to the traditional prognostic factors, but that effect was statistically nonsignificant (0.663 vs. 0.746, p = 0.124). RET/PTC1 rearrangement and nodal metastasis were significantly associated in all patients (p = 0.042), marginally associated in ptc patients (p = 0.051), but not associated in microptc patients (p = 0.700). RET/PTC1 rearrangement was not significantly associated with recurrent disease.
Conclusions
BRAF positivity is an independent predictor of recurrent disease in ptc.
Keywords: Papillary thyroid carcinoma, BRAF, RET/PTC1, recurrence
1. INTRODUCTION
The prevalence of thyroid cancer has been increasing worldwide1, including in China2. The disease has become the fastest-increasing cancer, and it ranks 5th among the most common cancers in women3. Notably, the current increase is almost entirely attributable to papillary thyroid carcinoma (ptc)4. The prognosis of differentiated thyroid cancer is benign, with a survival rate of 96.4% after 30 years follow-up5. However, a significant percentage of ptc patients experience recurrent disease or distant metastasis, reducing the survival rate to 40%6.
Several staging systems have been applied to stratify the risk of a poor outcome with ptc. However, all are based on histopathologic parameters after surgery7. They therefore cannot be used before an operation to determine the extent of surgery. With the emerging understanding of molecular genetics in thyroid cancer, several specific mutations in ptc have been determined8. The BRAF V600E mutation has been associated with worse prognostic features (such as extrathyroidal extension, lymph node metastasis or advanced tumour stage), poor clinical outcome, and mortality9–13. The RET/PTC oncogenes are believed to play an important role in radiation-induced ptc14. In contrast to BRAF mutation, RET/PTC rearrangement has been associated with better prognosis15. Yet despite those findings, controversy remains16–21. In addition, questions about the clinical significance of these mutations in the management of microptc are ongoing22.
We investigated the associations of BRAF V600E mutation and RET/PTC1 rearrangement with clinicopathologic features and outcomes in Chinese patients with ptc, including microptc.
2. METHODS
2.1. Patients
The board of medical ethics of Ruijin Hospital, Shanghai Jiaotong University, School of Medicine approved the study, and all patients gave written informed consent. The study enrolled 214 patients with histologically confirmed ptc who underwent surgery in Ruijin Hospital between November 2009 and May 2011. We performed genotyping analysis using frozen ptc tissue. Because of sample limitations, only 101 patients were analyzed for RET/PTC1 rearrangement. Patients were followed twice annually using, as necessary, tests for thyroid-stimulating hormone, thyroglobulin, thyroglobulin antibody; imaging by ultrasonography and computed tomography; and biopsy by fine-needle aspiration. Recurrent disease was defined by histologic or cytologic findings or by clinical appearance on imaging studies. Median follow-up was 36 months (range: 12–50 months), and the follow-up rate was 79.4%.
2.2. Detection of BRAF Mutation
Snap-frozen fresh tissues, including both cancerous and adjacent normal thyroid tissue, were collected by experienced pathologists and stored in liquid nitrogen until use. Evaluation of dna extracted using a dna purification kit (Omega Bio-Tek, Norcross, GA, U.S.A.) was performed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, U.S.A.). The presence of BRAF exon 15 mutation was determined by Sanger sequencing, as previously reported23. Polymerase chain reactions were performed in 25 μL buffer containing 1.5 mmol/L MgCl2, 200 mmol/L deoxynucleoside triphosphate, 50–100 ng genomic dna, 0.5 mmol/L each primer, and 2.5 U TaKaRa Taq dna polymerase (Takara Bio, Tokyo, Japan). Thirty-five cycles with annealing temperatures optimized at 60°C. Polymerase chain reaction product was purified and sequenced using an ABI Prism 3730 dna analyzer (Applied Biosystems, Foster City, CA, U.S.A.).
2.3. Detection of RET/PTC1 Rearrangement
Total rna was isolated using trizol (Invitrogen, Carlsbad, CA, U.S.A.) as described in the manufacturer’s protocol. An aliquot containing 1 μg total rna was reverse-transcribed using avian myeloblastosis virus reverse transcriptase (Promega, Madison, WI, U.S.A.), and RET/PTC1 was amplified by nested polymerase chain reaction, separated on 1.2% agarose gel, and visualized under ultraviolet illumination as previously reported24. As a positive control, rna from the TPC1 cell line was used.
2.4. Statistical Analysis
Statistical analyses were performed using SPSS Statistics (version 17.0: SPSS, Chicago, IL, U.S.A.) and MedCalc (version 13.0: MedCalc Software, Ostend, Belgium). The Fisher exact test was used for nominal variables, and the Mann–Whitney nonparametric test was used for continuous variables. Univariate and multivariate logistic regression were used to determine the risk factors associated with recurrent disease. Odds ratios (ors) were calculated by exponentiation of logistic regression analysis and reported with 95% confidence intervals (cis). To measure the discriminative improvement attributable to the risk score for recurrent disease, we plotted receiver operating characteristic curves for two logistic regression models: Model 1, which included traditional prognostic factors (that is, age, sex, thyroid capsule invasion, multicentricity, TNM stage), and Model 2, which included the traditional factors, plus BRAF mutation. All p values are two-tailed, and p < 0.05 was accepted as statistically significant.
3. RESULTS
3.1. Clinicopathologic Characteristics
As Table i shows, microptc accounted for 30.4% of the tumours in the study group; most patients (65.0%) presented stage i or ii disease. No distant metastases were found at first diagnosis; of the 170 patients who were subsequently followed, 15 (8.8%) experienced recurrent disease.
TABLE I.
Clinicopathologic features in 214 cases of papillary thyroid carcinoma (ptc)
| Feature | Value |
|---|---|
| Sex (n men/women) | 66/148 |
| Mean age (years) | 43±12 |
| Hashimoto disease [n (%)] | 31 (14.5) |
| Microptc [n (%)] | 65 (30.4) |
| Multicentricity [n (%)] | 49 (22.9) |
| Thyroid capsule invasion [n (%)] | 76 (35.5) |
| Tumour size | |
| Mean (cm) | 1.6±0.9 |
| Category [n (%)] | |
| ≤1 cm | 65 (30.4) |
| ≤2 cm | 104 (48.6) |
| ≤4 cm | 43 (20.1) |
| >4 cm | 2 (0.9) |
| Nodal metastases | 106 (49.5) |
| Stagea [n (%)] | |
| i | 135 (63.1) |
| ii | 4 (1.9) |
| iii | 38 (17.8) |
| iv | 37 (17.3) |
| BRAF V600E [n (%)] | 147 (68.7) |
| RET/PTC1b [n (%)] | 26 (25.7) |
| Recurrence-free survival [n (%)] | 155 (91.2c) |
Using the American Joint Committee on Cancer’s TNM classification system for differentiated thyroid carcinoma.
Because of sample limitations, only 101 analyses for RET/PTC1 rearrangement were performed.
Only 170 patients were followed.
A somatic BRAF V600E mutation was carried by 68.7% of all study patients, and a somatic RET/PTC1 rearrangement by 25.7% of the 101 whose samples could be tested. Dual mutations (BRAF and RET/PTC1) were harbored by 15 patients [14.9% (15 of 101)]. BRAF mutation was more prevalent in patients with ptc than with microptc (73.2% vs. 58.5%, p = 0.038, Table ii). No BRAF V601 mutation was found. No BRAF mutation or RET/PTC1 rearrangement was found in the normal tissue adjacent to the ptc tumour.
TABLE II.
BRAF mutation and RET/PTC1 rearrangement in papillary thyroid carcinoma (ptc)
| Genetic characteristic | Disease type [n (%)] | p Value | ||
|---|---|---|---|---|
|
| ||||
| ptca | Microptcb | |||
| BRAF | Yes | 109 (73.2) | 38 (58.5) | 0.038 |
| No | 40 (26.9) | 27 (41.5) | ||
| RET/PTC1 | Yes | 16 (22.5) | 10 (33.3) | 0.320 |
| No | 55 (77.5) | 20 (66.7) | ||
Tumours greater than 1 cm in size.
Tumours 1 cm or less in size.
3.2. Correlations Between BRAF Mutation, RET/PTC1 Rearrangement, and Clinicopathological Characteristics of Patients with PTC
As shown in Table iii, BRAF mutation was significantly associated with Hashimoto disease (p = 0.000), ptc (p = 0.001), and microptc (p = 0.015). BRAF mutation was less prevalent in patients with Hashimoto disease (32.3%) than in those without (74.9%). We found no association between BRAF mutation and sex, age, multicentricity, thyroid capsule invasion, tumour stage, or nodal metastasis. We observed a nonsignificant trend toward positive BRAF mutation status in patients with tumours of advanced TNM stage (p = 0.176).
TABLE III.
Correlations between clinicopathologic features and BRAF mutation by papillary thyroid carcinoma (ptc) type
| Feature | BRAF-positive patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Overall | With ptca | With microptcb | ||||
|
|
|
|
||||
| [n (%)] | p Value | [n (%)] | p Value | [n (%)] | p Value | |
| Sex | ||||||
| Men | 49/66 (74.2) | 0.267 | 41/51 (80.4) | 0.176 | 8/15 (53.3) | 0.767 |
| Women | 98/148 (66.2) | 68/98 (69.4) | 30/50 (60.0) | |||
| Age | ||||||
| <45 Years | 68/103 (66.0) | 0.462 | 55/79 (69.6) | 0.356 | 13/24 (54.2) | 0.612 |
| ≥45 Years | 79/111 (71.2) | 54/70 (77.1) | 25/41 (61.0) | |||
| Hashimoto disease | ||||||
| Yes | 10/31 (32.3) | 0.000 | 6/17 (35.3) | 0.001 | 4/14 (28.6) | 0.015 |
| No | 137/183 (74.9) | 103/132 (78.0) | 34/51 (66.7) | |||
| Multicentricity | ||||||
| Yes | 34/49 (69.4) | 1.000 | 27/37 (73.0) | 1.000 | 7/12 (58.3) | 1.000 |
| No | 113/165 (68.5) | 82/112 (73.2) | 31/53 (58.5) | |||
| Thyroid capsule invasion | ||||||
| Yes | 56/76 (73.7) | 0.282 | 51/67 (76.1) | 0.578 | 5/9 (55.6) | 1.000 |
| No | 91/138 (65.9) | 58/82 (70.7) | 33/56 (58.9) | |||
| T-Stagec | ||||||
| T1–2 | 90/137 (65.7) | 0.223 | 57/81 (70.4) | 0.460 | 33/56 (58.9) | 1.000 |
| T3–4 | 57/77 (74.0) | 52/68 (76.5) | 5/9 (55.6) | |||
| Nodal metastasis | ||||||
| Yes | 69/106 (65.1) | 0.303 | 54/76 (71.1) | 0.584 | 15/30 (50.0) | 0.219 |
| No | 78/108 (72.2) | 55/73 (75.3) | 23/35 (65.7) | |||
| Stagec | ||||||
| i–ii | 94/139 (67.6) | 0.758 | 68/98 (69.4) | 0.176 | 26/41 (63.4) | 0.310 |
| iii–iv | 53/75 (70.7) | 41/51 (80.4) | 12/24 (50.0) | |||
Tumours greater than 1 cm in size.
Tumours 1 cm or less in size.
Using the American Joint Committee on Cancer’s TNM classification system for differentiated thyroid carcinoma.
In tested patients, RET/PTC1 rearrangement was significantly associated with nodal metastasis (p = 0.042) and marginally with ptc (p = 0.051), but not with microptc (p = 0.700). We found no significant association of RET/PTC1 rearrangement with other clinicopathologic features (Table iv).
TABLE IV.
Correlations between clinicopathologic features and RET/PTC1 rearrangement by papillary thyroid carcinoma (ptc) type
| Feature | RET/PTC1-positive patients | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Overall | With ptca | With microptcb | ||||
|
|
|
|
||||
| [n (%)] | p Value | [n (%)] | p Value | [n (%)] | p Value | |
| Sex | ||||||
| Men | 7/30 (23.3) | 0.807 | 5/22 (22.7) | 1.000 | 2/8 (25.0) | 0.682 |
| women | 19/71 (26.8) | 11/49 (22.4) | 8/22 (36.4) | |||
| Age | ||||||
| <45 Years | 11/41 (26.8) | 1.000 | 9/31 (29.0) | 0.268 | 2/10 (20.0) | 0.419 |
| ≥45 Years | 15/60 (25.0) | 7/40 (17.5) | 8/20 (40.0) | |||
| Hashimoto disease | ||||||
| Yes | 7/19 (36.8) | 0.249 | 5/11 (45.5) | 0.109 | 2/8 (25.0) | 0.682 |
| No | 19/82 (23.2) | 11/60 (18.3) | 8/22 (36.4) | |||
| Multicentricity | ||||||
| Yes | 6/19 (31.6) | 0.565 | 4/16 (25.0) | 0.746 | 2/3 (66.7) | 0.251 |
| No | 20/82 (24.4) | 12/55 (21.8) | 8/27 (29.6) | |||
| Thyroid capsule invasion | ||||||
| Yes | 9/31 (29.0) | 0.629 | 8/28 (28.6) | 0.389 | 1/3 (33.3) | 1.000 |
| No | 17/70 (24.3) | 8/43 (18.6) | 9/27 (33.3) | |||
| T-Stagec | ||||||
| T1–2 | 17/69 (24.6) | 0.808 | 8/42 (19.0) | 0.406 | 9/27 (33.3) | 1.000 |
| T3–4 | 9/32 (28.1) | 8/29 (27.6) | 1/3 (33.3) | |||
| Nodal metastases | ||||||
| Yes | 17/48 (35.4) | 0.042 | 11/33 (33.3) | 0.051 | 6/15 (40.0) | 0.700 |
| No | 9/53 (17.0) | 5/38 (13.2) | 4/15 (26.7) | |||
| Stagec | ||||||
| i–ii | 14/63 (22.2) | 0.350 | 9/43 (20.9) | 0.774 | 5/20 (25.0) | 0.231 |
| iii–iv | 12/38 (31.6) | 7/28 (25.0) | 5/10 (50.0) | |||
Tumours greater than 1 cm in size.
Tumours 1 cm or less in size.
Using the American Joint Committee on Cancer’s TNM classification system for differentiated thyroid carcinoma.
3.3. Prognostic Factors Associated with Recurrent Disease
We found recurrent disease in 15 patients. Tumour size and BRAF mutation status were associated with recurrence. Recurrent tumours were larger (2.0 ± 0.2 cm vs. 1.5 ± 0.1 cm, p = 0.017) and more likely to harbour BRAF mutation (93.3% vs. 64.5%, p = 0.022, Table v). No association of recurrent disease with Hashimoto disease, TNM stage, type of surgery, or RET/PTC1 rearrangement was found. Multivariate analysis confirmed that tumour size and BRAF mutation were independent prognostic factors associated with recurrent ptc (Table vi). Compared with patients whose tumours lacked the somatic BRAF V600E mutation, patients with tumours harbouring the mutation had a risk of recurrent disease that was increased by a factor of 9 (or: 9.072; 95% ci: 1.072 to 76.739; p = 0.043). Table vii shows correlations between BRAF mutation and other clinicopathologic variables.
TABLE V.
Factors prognostic for survival in 170 patients with papillary thyroid carcinoma (ptc)
| Factor | Recurrence | p Value | |
|---|---|---|---|
|
| |||
| No | Yes | ||
| Mean tumour size (cm) | 1.5±0.1 | 2.0±0.2 | 0.017 |
| Mean age (years) | 44±1 | 46±3 | 0.711 |
| Age category (n) | |||
| <45 Years | 69 | 4 | 0.275 |
| ≥45 Years | 86 | 11 | |
| Sex (n) | |||
| Men | 49 | 7 | 0.258 |
| Women | 106 | 8 | |
| Hashimoto disease (n) | |||
| Yes | 25 | 3 | 0.716 |
| No | 130 | 12 | |
| Microptc (n) | |||
| Yes | 53 | 2 | 0.148 |
| No | 102 | 13 | |
| Multicentricity (n) | |||
| Yes | 32 | 2 | 0.738 |
| No | 123 | 13 | |
| Thyroid capsule invasion (n) | |||
| Yes | 53 | 5 | 1.000 |
| No | 102 | 10 | |
| T-Stagea (n) | |||
| T1–2 | 102 | 9 | 0.777 |
| T3–4 | 53 | 6 | |
| Nodal metastases (n) | |||
| Yes | 72 | 8 | 0.788 |
| No | 83 | 7 | |
| Stagea (n) | |||
| i–ii | 98 | 7 | 0.267 |
| iii–iv | 57 | 8 | |
| Thyroid surgery (n) | |||
| Total thyroidectomy | 69 | 8 | 0.408 |
| Subtotal thyroidectomy | 66 | 7 | |
| Lobectomy | 20 | 0 | |
| Lymph node dissection (n) | |||
| No | 48 | 6 | 0.528 |
| Central | 75 | 5 | |
| Central and lateral | 32 | 4 | |
| BRAF mutation (n) | |||
| Yes | 100 | 14 | 0.022 |
| No | 55 | 1 | |
| RET/PTC1 rearrangement (n) | |||
| Yes | 20 | 2 | 1.000 |
| No | 51 | 4 | |
Using the American Joint Committee on Cancer’s TNM classification system for differentiated thyroid carcinoma.
TABLE VI.
Univariate and multivariate analysis of clinicopathologic features and recurrence-free survival in papillary thyroid carcinoma (ptc)
| Feature | Analysis | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Univariate | Multivariate | |||||
|
|
|
|||||
| or | 95% ci | p Value | or | 95% ci | p Value | |
| Male sex | 1.893 | 0.650 to 5.515 | 0.242 | 1.471 | 0.459 to 4.715 | 0.516 |
| Age | 1.008 | 0.966 to 1.052 | 0.717 | 0.978 | 0.923 to 1.036 | 0.445 |
| Multicentricity | 0.591 | 0.127 to 2.755 | 0.503 | 0.256 | 0.037 to 1.785 | 0.169 |
| Thyroid capsule invasion | 0.962 | 0.313 to 2.960 | 0.947 | 0.267 | 0.058 to 1.226 | 0.089 |
| Stage iii–iv | 1.965 | 0.677 to 5.703 | 0.214 | 5.216 | 0.989 to 27.518 | 0.052 |
| Tumour size | 1.639 | 1.012 to 2.656 | 0.045 | 2.387 | 1.197 to 4.761 | 0.013 |
| BRAF mutation | 7.700 | 0.986 to 60.128 | 0.052 | 9.072 | 1.072 to 76.739 | 0.043 |
TABLE VII.
Correlations between BRAF mutation and other variables in the multivariate model
| Variable | Presence of BRAF mutation | |
|---|---|---|
|
| ||
| Correlation coefficient a | p Value | |
| Age | 0.132 | 0.086 |
| Sex | 0.039 | 0.618 |
| Multicentricity | −0.025 | 0.746 |
| Capsule invasion | 0.056 | 0.471 |
| Stage | 0.088 | 0.255 |
| Tumour size | 0.123 | 0.110 |
Spearman rho.
We further evaluated the incremental value of BRAF (with respect to traditional prognostic factors) to predict recurrent disease. The area under the receiver operating characteristic curve was calculated for two models: Model 1 included the traditional prognostic factors (age at diagnosis, sex, thyroid capsule invasion, multicentricity, and stage); Model 2 included the Model 1 variables, plus BRAF mutation. As Figure 1 and Table viii show, the area under the curve was 0.663 (95% ci: 0.529 to 0.797) for Model 1 and 0.746 (95% ci: 0.631 to 0.860) for Model 2—achieving a nonsignificant increase of 8.3% with the addition of BRAF mutation (p = 0.124).
FIGURE 1.
Predictability of recurrent papillary thyroid carcinoma using combined prediction models. Model 1 included traditional prognostic factors (age, sex, thyroid capsule invasion, multicentricity, TNM stage), and Model 2 included traditional factors, plus BRAF mutation. The area under the curve was 0.663 (95% confidence interval: 0.529 to 0.797) for Model 1, and 0.746 (95% confidence interval: 0.631 to 0.860) for Model 2. The addition of BRAF mutation to traditional prognostic factors increased the predictability by 8.3%, but without statistical significance (p = 0.124).
TABLE VIII.
Predictability of recurrent papillary thyroid carcinoma, measured by area under the curve (auc)
Calculated from logistic regression. Model 1 = –3.323 – 0.018(age in years) + 0.645(sex: male=1, female=0) – 0.667(multicentricity: yes=1, no=0) – 0.434(thyroid capsule invasion: yes=1, no=0) + 1.233(stage iii–iv=1, i–ii=0); Model 2 = –5.094 – 0.022(age in years) + 0.651(sex: male=1,; female=0) – 0.795(multicentricity: yes=1, no=0) – 0.715(thyroid capsule invasion: yes=1, no=0) + 1.443(stage iii/iv=1, i–ii=0) + 2.150(BRAF mutation: yes=1, no=0). A higher prediction score corresponds to a higher risk of recurrence.
Model 1 versus model 2.
Included traditional prognostic factors (that is, age, sex, thyroid capsule invasion, multicentricity, TNM stage).
Included traditional factors plus BRAF mutation.
4. DISCUSSION
In the present study, we genotyped ptc tumours and investigated the associations of mutations with clinicopathologic features and clinical outcome. We found that BRAF mutation was an independent predictor of recurrent disease, although it not associated with advanced clinicopathologic features; on the other hand, RET/PTC1 rearrangement was associated with nodal disease, but not with recurrent disease.
Although most ptc patients experience favourable outcomes, significant numbers of patients develop recurrent disease and experience poor outcomes. To improve clinical outcomes, disease staging systems have been established to stratify management strategies25. Large tumour size, older age, extrathyroidal invasion, male sex, multicentricity, distant metastasis, and lymph node metastasis are the main determinants of a poor outcome in ptc patients6,25–27. Currently, the need for preoperative risk stratification and for the enlarged “grey zone” of microptc require an optimized risk scoring system. Genetic markers such as BRAF mutation and RET/PTC rearrangements seem to be able to fill the gap. Positivity for BRAF mutation has been associated with a negative prognosis and poor clinical outcome. However, conflicting data have also been reported. The clinical significance of BRAF analysis in ptc patients has been disputed because the association of positivity with poor outcome was believed to depend on the mutation’s association with aggressive tumour behavior. Our data provide an important piece of evidence to help resolve the dispute. We did not find a significant association of BRAF mutation with negative prognostic indicators such as large tumour size, old age, extrathyroidal invasion, male sex, multicentricity, lymph node metastasis, or TNM stage. However, BRAF mutation and tumour size were both associated with recurrent disease (although not with tumour stage and extent of surgery). Compared with patients lacking a BRAF mutation, those with the mutation were more likely (by a factor of 9) to experience recurrent disease. BRAF analysis provided an 8.3% increment over traditional predictors for recurrent disease, but that increase was not statistically significant (p = 0.124). Our data confirm the clinical significance of BRAF analysis in ptc patients and suggest a need for more extensive surgery and for more aggressive postsurgical management such as radioactive iodine ablation, suppression of thyroid-stimulating hormone below 0.1 mU/L, and closer follow-up in somatic BRAF carriers. However, knowing a patient’s BRAF status did not substantially improve prediction overall, probably because of the limited number of recurrence events.
The lack of any associations between BRAF mutation and advanced clinicopathologic features might have several explanations. First, our cohort came from a single centre serving patients from Shanghai and its surrounding area, where iodine is sufficient. Guan et al.28 reported that high iodine intake is a significant risk factor for BRAF mutation, and a meta-analysis showed that a high prevalence of the BRAF V600E mutation tended to have a smaller meta-risk of extrathyroidal invasion and lymph node metastasis7. Second, a significant number of our patients underwent subtotal thyroidectomy or lobectomy, which might lead to an underestimation of aggressive pathologic characteristics21,29. Consistent with an earlier study7, BRAF mutation was confirmed as an independent predictor of recurrence in our cohort at 3 years of follow-up. Our data indicate the importance of performing follow-up studies.
Other important findings of our study include the observation that, in addition to BRAF mutation, tumour size is another independent predictor of recurrent ptc. Also, BRAF V600E was, in general, less prevalent in microptc than in ptc, which is consistent with most earlier studies7,13. In addition, BRAF mutation was inversely associated with Hashimoto disease, which has also been reported in a Korean cohort30. This inverse correlation suggests that BRAF mutation and Hashimoto disease are exclusively involved in ptc initiation. Moreover, where dual mutation of BRAF and RET/PTC1 occurred (15 patients), 16.7% experienced recurrent disease, compared with the 11.8% of patients harbouring solely a BRAF mutation (p = 0.664, Table ix). That observation is consistent with an earlier finding that patients with dual mutation are more susceptible to recurrent disease31.
TABLE IX.
Prevalence of sole and dual BRAF mutations in recurrent and recurrence-free papillary thyroid carcinoma
| Mutation status | Recurrence [n (%)] | p Value | |
|---|---|---|---|
|
| |||
| No | Yes | ||
| BRAF-positive only | 30 (88.2) | 4 (11.8) | 0.664 |
| BRAF- and RET/PTC1-positive | 10 (83.3) | 2 (16.7) | |
The limitations of our study include its lack of multicentre data and long-term follow-up. The limitation resulting from extent of surgery has already been discussed. Papillary thyroid carcinoma is slow-growing. Long-term follow-up, including data on both recurrence and mortality, is required to comprehensively elucidate the role of BRAF mutation analysis in the management of this most frequent thyroid cancer.
5. CONCLUSIONS
We analyzed both BRAF mutation and RET/PTC1 rearrangement in 214 Chinese ptc patients with a median follow-up of 36 months. We found that BRAF mutation was an independent predictor of recurrent disease despite a lack of association with advanced clinicopathologic features. Our data indicate that BRAF mutation is not just a marker of aggressiveness, but a true prognostic factor. Although the increase was nonsignificant, BRAF mutation analysis added prognostic value over that of traditional predictors. In accord with previous studies, we suggest that BRAF mutation analysis has a positive role to play in the presurgical assessment of ptc patients. However, larger series and longer-term follow-up data are required.
6. ACKNOWLEDGMENTS
This study was supported by the grants from Science and Technology Commission of Shanghai (13QH1402000) and Key Project of the Science and Technology Commission of Shanghai (10411951100). We thank Professor Min Xu from the Clinical Epidemiology Group in the Shanghai Institute of Endocrine and Metabolic Disease for statistical assistance.
7. CONFLICT OF INTEREST DISCLOSURES
All authors declare no competing financial interests with respect to the preparation of this work.
8. REFERENCES
- 1.Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–7. doi: 10.1002/cncr.24416. [DOI] [PubMed] [Google Scholar]
- 2.Wang Y, Wang W. Increasing incidence of thyroid cancer in Shanghai, China, 1983–2007. Asia Pac J Public Health. 2012 doi: 10.1177/1010539512436874. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
- 3.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60:277–300. doi: 10.3322/caac.20073. [DOI] [PubMed] [Google Scholar]
- 4.Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7. doi: 10.1001/jama.295.18.2164. [DOI] [PubMed] [Google Scholar]
- 5.Elisei R, Molinaro E, Agate L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab. 2010;95:1516–27. doi: 10.1210/jc.2009-1536. [DOI] [PubMed] [Google Scholar]
- 6.Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306. doi: 10.1056/NEJM199801293380506. [DOI] [PubMed] [Google Scholar]
- 7.Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–90. doi: 10.1210/jc.2007-1179. [DOI] [PubMed] [Google Scholar]
- 8.Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118:1764–73. doi: 10.1002/cncr.26500. [DOI] [PubMed] [Google Scholar]
- 9.Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97:4390–8. doi: 10.1210/jc.2012-1775. [DOI] [PubMed] [Google Scholar]
- 10.Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559–70. doi: 10.1210/jc.2012-2104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 2009;27:2977–82. doi: 10.1200/JCO.2008.20.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501. doi: 10.1001/jama.2013.3190. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Walczyk A, Kowalska A, Kowalik A, et al. The BRAF V600E mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome? Clin Endocrinol (Oxf) 2014;80:899–904. doi: 10.1111/cen.12386. [DOI] [PubMed] [Google Scholar]
- 14.Nikiforov YE, Rowland JM, Bove KE, Monforte–Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4. [PubMed] [Google Scholar]
- 15.Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4:287–94. [PubMed] [Google Scholar]
- 16.Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A. BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg. 2014;38:679–87. doi: 10.1007/s00268-013-2223-2. [DOI] [PubMed] [Google Scholar]
- 17.Gouveia C, Can NT, Bostrom A, Grenert JP, van Zante A, Orloff LA. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg. 2013;139:1164–70. doi: 10.1001/jamaoto.2013.4501. [DOI] [PubMed] [Google Scholar]
- 18.Brzezianska E, Pastuszak–Lewandoska D, Wojciechowska K, et al. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett. 2007;28:351–9. [PubMed] [Google Scholar]
- 19.Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239–43. doi: 10.1111/j.1365-2265.2004.02089.x. [DOI] [PubMed] [Google Scholar]
- 20.Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588–93. doi: 10.1111/j.1365-2265.2005.02389.x. [DOI] [PubMed] [Google Scholar]
- 21.Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56:89–97. doi: 10.1507/endocrj.K08E-208. [DOI] [PubMed] [Google Scholar]
- 22.Soares P, Sobrinho–Simões M. Cancer: small papillary thyroid cancers—is BRAF of prognostic value? Nat Rev Endocrinol. 2011;7:9–10. doi: 10.1038/nrendo.2010.213. [DOI] [PubMed] [Google Scholar]
- 23.Qing W, Fang WY, Ye L, et al. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid. 2012;22:905–10. doi: 10.1089/thy.2011.0452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wang YL, Wang JC, Wu Y, et al. Incidentally simultaneous occurrence of RET/PTC, H4–PTEN and BRAF mutation in papillary thyroid carcinoma. Cancer Lett. 2008;263:44–52. doi: 10.1016/j.canlet.2007.12.018. [DOI] [PubMed] [Google Scholar]
- 25.Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010;22:395–404. doi: 10.1016/j.clon.2010.05.004. [DOI] [PubMed] [Google Scholar]
- 26.Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28. doi: 10.1016/0002-9343(94)90321-2. [DOI] [PubMed] [Google Scholar]
- 27.Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from pappilary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892–9. doi: 10.1210/jc.2005-2838. [DOI] [PubMed] [Google Scholar]
- 28.Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612–17. doi: 10.1210/jc.2008-2390. [DOI] [PubMed] [Google Scholar]
- 29.Xing M. [Comments on the Ito et al. article (Endocr J 2008 Oct 8 Epub ahead of print)] The lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution. Endocr J. 2009;56:305–6. doi: 10.1507/endocrj.K08E-335. [DOI] [PubMed] [Google Scholar]
- 30.Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid. 2009;19:137–41. doi: 10.1089/thy.2008.0144. [DOI] [PubMed] [Google Scholar]
- 31.Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 2009;15:485–91. doi: 10.1158/1078-0432.CCR-08-0933. [DOI] [PMC free article] [PubMed] [Google Scholar]